Sage Journals: Discover world-class research

Abstract

Background:

The Neurostatus-eEDSS is an electronic tool providing automated real-time feedback on inconsistencies of Neurostatus-EDSS calculations.

Objective:

To analyze the performance of the Neurostatus-eEDSS in two multicenter phase 3 multiple sclerosis (MS) trials.

Methods:

All assessments captured with the Neurostatus-eEDSS web service during a period of 2.5 years were analyzed.

Results:

Of the total 10,789 assessments, 40.1% had inconsistencies after first entry, reduced to 22.1% due to the real-time feedback. The entire checking process resulted in a change of the expanded disability status scale (EDSS) score in 14.8% of the assessments.

Conclusion:

The Neurostatus-eEDSS can increase consistency and reliability of EDSS assessments in clinical MS trials.

Keywords

Disability trials digital neurostatus EDSS

Get full access to this article

View all access options for this article.

References

Wiendl

Meuth

SG.

Pharmacological approaches to delaying disability progression in patients with multiple sclerosis. Drugs 2015; 75(9): 947–977.

Montalban

Hauser

Kappos

, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376(3): 209–220.

Kappos

Bar-Or

Cree

BAC

, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263–1273.

Lublin

Miller

Freedman

, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387(10023): 1075–1084.

Hauser

Bar-Or

Comi

, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376(3): 221–234.

Meyer-Moock

Feng

Y-S

Maeurer

, et al. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14: 58.

Cohen

Reingold

Polman

, et al; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinical trials: Current status and future prospects. Lancet Neurol 2012; 11(5): 467–476.

D’Souza

Yaldizli

John

, et al. Neurostatus e-Scoring improves consistency of expanded disability status scale assessments: A proof of concept study. Mult Scler 2017; 23(4): 597–603.

ClinicalTrials.gov. Efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing multiple sclerosis (ASCLEPIOS I and II), https://clinicaltrials.gov/ct2/show/NCT02792218; https://clinicaltrials.gov/ct2/show/NCT02792231 (accessed 13 November 2018).

10.

Neurostatus.net. Kappos L - Neurostatus scoring definitions (Version 04/10.2), 2011, https://www.neurostatus.net/ (accessed 26 December 2018).

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.53 MB